Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Liu

Showing results (281-290 of 361) with videos related to

Pageof 37
Sort By:
JTO Clinical and Research Reports|September 25, 2024
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 StudyJoel W Neal, Armando Santoro, Maria Gonzalez-Cao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2017
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJoshua Bauml, Tanguy Y Seiwert, David G Pfister, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2015
Outpatient Autologous Stem Cell Transplantation for Patients With MyelomaThomas M Paul, Stephen V Liu, Elise A Chong, et al.
Cancer Chemotherapy and Pharmacology|August 22, 2018
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumorsStephen V Liu, Susan G Groshen, Karen Kelly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trialA S Mansfield, A Każarnowicz, N Karaseva, et al.
Future Oncology (London, England)|February 13, 2024
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring <i>NRG1</i> gene fusionsDong-Wan Kim, Alison M Schram, Antoine Hollebecque, et al.
Journal of the American Chemical Society|October 18, 2013
Geometric and electronic structure of the Mn(IV)Fe(III) cofactor in class Ic ribonucleotide reductase: correlation to the class Ia binuclear non-heme iron enzymeYeonju Kwak, Wei Jiang, Laura M K Dassama, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2025
50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow's Guide in the ClinicJarushka Naidoo, Abesh Niroula, Dipesh Uprety, et al.
JCO Precision Oncology|December 27, 2021
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring <i>MET</i> Exon 14 SkippingXiuning Le, Lingzhi Hong, Chuck Hensel, et al.
The Oncologist|August 28, 2020
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case SeriesJacques Cadranel, Stephen V Liu, Michaël Duruisseaux, et al.
Pageof 37

Showing results (281-290 of 361) with videos related to

Sort By:
Pageof 37
JTO Clinical and Research Reports|September 25, 2024
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 StudyJoel W Neal, Armando Santoro, Maria Gonzalez-Cao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2017
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJoshua Bauml, Tanguy Y Seiwert, David G Pfister, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2015
Outpatient Autologous Stem Cell Transplantation for Patients With MyelomaThomas M Paul, Stephen V Liu, Elise A Chong, et al.
Cancer Chemotherapy and Pharmacology|August 22, 2018
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumorsStephen V Liu, Susan G Groshen, Karen Kelly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trialA S Mansfield, A Każarnowicz, N Karaseva, et al.
Future Oncology (London, England)|February 13, 2024
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring <i>NRG1</i> gene fusionsDong-Wan Kim, Alison M Schram, Antoine Hollebecque, et al.
Journal of the American Chemical Society|October 18, 2013
Geometric and electronic structure of the Mn(IV)Fe(III) cofactor in class Ic ribonucleotide reductase: correlation to the class Ia binuclear non-heme iron enzymeYeonju Kwak, Wei Jiang, Laura M K Dassama, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2025
50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow's Guide in the ClinicJarushka Naidoo, Abesh Niroula, Dipesh Uprety, et al.
JCO Precision Oncology|December 27, 2021
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring <i>MET</i> Exon 14 SkippingXiuning Le, Lingzhi Hong, Chuck Hensel, et al.
The Oncologist|August 28, 2020
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case SeriesJacques Cadranel, Stephen V Liu, Michaël Duruisseaux, et al.
Pageof 37